Related Experiment Videos
Reduction in Seizure Generalization Associated With Long-Term Low-Dose Immunomodulatory Therapy Using Prednisolone
1Outpatient Department, Research Institute of Virology of the Republican Specialized Scientific and Practical Medical Center of Epidemiology, Microbiology, Infectious and Parasitic Diseases, Tashkent, Tashkent State, Uzbekistan.
Objective:
Rett syndrome is a severe neurodevelopmental disorder most commonly associated with pathogenic variants of the MECP2 gene and frequently accompanied by epilepsy. Seizures occur in a substantial proportion of patients and may be resistant to conventional antiepileptic therapy. Emerging evidence suggests that neuroinflammatory processes may contribute to seizure propagation and represent a potential therapeutic target.
Case Report:
A girl born at term with initially normal early development is described. At approximately 2 years of age, she developed regression of speech and stereotypic hand movements, accompanied by seizures and other neurological features consistent with Rett syndrome. The patient received long-term therapy consisting of low-dose prednisolone and methotrexate in addition to anticonvulsant treatment. During follow-up, a reduction in seizure generalization and a shift in seizure pattern were observed, with generalized seizures becoming less frequent and replaced by brief focal seizures without secondary generalization.
Conclusion:
In this single case, long-term low-dose prednisolone and methotrexate therapy was associated with a reduction in seizure generalization. Although a causal relationship cannot be established, this observation supports the hypothesis that immunomodulatory mechanisms may influence seizure propagation in pharmacoresistant epilepsy.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Electroconvulsive Therapy
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...